ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 001,80
-0,48%
Dow Jones
38 798,99
-0,22%
DAX
18 557,27
-0,48%
Brent Oil
79,395
0,00%
Bitcoin
69 249,13
-0,12%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Canadá
  5. TSXV
  6. Psybio Therapeutics Corp (PSYB)

  7. Psybio Therapeutics Corp (PSYB) Actualités

PSYB

Psybio Therapeutics (PSYB)

Psybio Therapeutics Corp
De:
Trier par:
 Showing the most relevant articles for your search:TSXV:PSYB
DateHeureSourceTitreSymboleSociété
07/12/202306h25PR Newswire (Canada)TSX Venture Exchange Stock Maintenance BulletinsTSXV:PSYBPsybio Therapeutics Corp
06/12/202314h32PR Newswire (Canada)Suspension de la négociation par l'Organisme canadien de réglementation des investissements - PSYBTSXV:PSYBPsybio Therapeutics Corp
06/12/202314h30PR Newswire (Canada)Canadian Investment Regulatory Organization Trading Halt - PSYBTSXV:PSYBPsybio Therapeutics Corp
08/12/202214h01PR Newswire (Canada)PsyBio Therapeutics Takes Initial Step to Help Protect the Sonoran Desert Toad as it Files Three New Provisional Patent Applications, Including Intellectual Property Protection for the Biosynthetic Production of 5-MeO-DMTTSXV:PSYBPsybio Therapeutics Corp
06/12/202214h09PR Newswire (Canada)PsyBio Therapeutics Files Four U.S. Patent Cooperation Treaty (PCT) Patent Applications Further Expanding Its Patent PortfolioTSXV:PSYBPsybio Therapeutics Corp
01/12/202213h30PR Newswire (Canada)PsyBio Therapeutics Announces Non-Brokered Private Placement FinancingTSXV:PSYBPsybio Therapeutics Corp
29/11/202213h20PR Newswire (Canada)PsyBio Therapeutics Reports Third Quarter 2022 Financial ResultsTSXV:PSYBPsybio Therapeutics Corp
11/10/202213h30PR Newswire (Canada)PsyBio Therapeutics Reaches Agreement to Conduct Initial Psilocybin Clinical TrialTSXV:PSYBPsybio Therapeutics Corp
19/09/202213h30PR Newswire (Canada)PsyBio Therapeutics Latest U.S. PCT (Non-Provisional) Patent Application AcceptedTSXV:PSYBPsybio Therapeutics Corp
07/09/202213h30PR Newswire (Canada)PsyBio Therapeutics to Present at Upcoming Investor Events in September 2022TSXV:PSYBPsybio Therapeutics Corp
29/08/202213h30PR Newswire (Canada)PsyBio Therapeutics Reports Second Quarter 2022 Financial ResultsTSXV:PSYBPsybio Therapeutics Corp
11/08/202213h30PR Newswire (Canada)PsyBio Therapeutics Strengthens IP Portfolio through Filing of Data to Support Previously Submitted Provisional Biosynthetic Production Patent ApplicationTSXV:PSYBPsybio Therapeutics Corp
08/08/202213h30PR Newswire (Canada)PsyBio Therapeutics Announces Expansion of Patent Portfolio with Additional Global Patent ApplicationsTSXV:PSYBPsybio Therapeutics Corp
27/06/202223h05PR Newswire (Canada)PsyBio Therapeutics to Seek Approval of Proposed Share Consolidation at Annual and Special Meeting of ShareholdersTSXV:PSYBPsybio Therapeutics Corp
02/06/202213h30PR Newswire (Canada)PsyBio Therapeutics Initiates Commercial Biosynthetic Based Process Development for Psycho-Targeted and Psychoactive CompoundsTSXV:PSYBPsybio Therapeutics Corp
30/05/202213h25PR Newswire (Canada)PsyBio Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update on Intellectual Property and Clinical Development MilestonesTSXV:PSYBPsybio Therapeutics Corp
16/05/202213h30PR Newswire (Canada)PsyBio Therapeutics Develops Commercial Purification Process for Second Generation Psycho-Targeted CompoundTSXV:PSYBPsybio Therapeutics Corp
06/05/202213h30PR Newswire (Canada)PsyBio Therapeutics Initiates Blood-Brain Barrier Permeability Testing for Pipeline Compounds to Enhance Portfolio DevelopmentTSXV:PSYBPsybio Therapeutics Corp
27/04/202213h30PR Newswire (Canada)PsyBio Therapeutics Begins Filing Global Provisional Patent Conversion Applications to Further Strengthen Biosynthetic Patent PortfolioTSXV:PSYBPsybio Therapeutics Corp
19/04/202213h30PR Newswire (Canada)PsyBio Therapeutics to Participate in Upcoming Investor Conferences in April 2022TSXV:PSYBPsybio Therapeutics Corp
13/04/202213h30PR Newswire (Canada)PsyBio Therapeutics Initiates Clinical Trial Site Selection ProcessTSXV:PSYBPsybio Therapeutics Corp
23/03/202212h30PR Newswire (Canada)PsyBio Therapeutics to Participate in the 2022 Maxim Group Virtual Growth Conference on March 28-30, 2022TSXV:PSYBPsybio Therapeutics Corp
15/03/202212h30PR Newswire (Canada)PsyBio Therapeutics Announces Proposed Acquisition of Everest Pharma (Pty) Ltd., a Lesotho Company in Southern Africa, as Part of Its Ongoing Impact Investment StrategyTSXV:PSYBPsybio Therapeutics Corp
03/03/202201h24PR Newswire (Canada)PsyBio Therapeutics Reports Annual 2021 Financial ResultsTSXV:PSYBPsybio Therapeutics Corp
02/02/202214h34PR Newswire (Canada)PsyBio Therapeutics to Participate in Citi's Psychedelic Drug Video Call SeriesTSXV:PSYBPsybio Therapeutics Corp
10/01/202212h30PR Newswire (Canada)PsyBio Therapeutics to Present at the H.C. Wainwright Bioconnect ConferenceTSXV:PSYBPsybio Therapeutics Corp
07/12/202113h30PR Newswire (Canada)PsyBio Therapeutics Successfully Completes First Pre-IND Meeting with the United States Food and Drug AdministrationTSXV:PSYBPsybio Therapeutics Corp
02/12/202113h30PR Newswire (Canada)PsyBio Therapeutics Sponsors 16 Collaborative Research Abstract Presentations at Two Scientific ConferencesTSXV:PSYBPsybio Therapeutics Corp
01/12/202113h30PR Newswire (Canada)PsyBio Therapeutics to Present at the H.C. Wainwright 2nd Annual Psychedelics ConferenceTSXV:PSYBPsybio Therapeutics Corp
30/11/202113h30PR Newswire (Canada)PsyBio Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update on Intellectual Property and Clinical Development MilestonesTSXV:PSYBPsybio Therapeutics Corp
 Showing the most relevant articles for your search:TSXV:PSYB

Dernières Valeurs Consultées

COIN
UBEXBTC
Ubex
USOTC
MEYYY
Medco Energi Internasion... (PK)
USOTC
MSCRF
Mito Securities (PK)
BOV
F1AN34R
Diamondback Energy
BIT
JPSRE
UBS ETF MSCI Japan SocRe...
EU
ALWTR
Osmosun
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés